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orientations (1,683 by telephone and 903 by electronic mail). Forty-nine percent of 
the requests were made by the patients, 45% by a family member and 2% by health 
care professionals. Among all requests, 77% were regarding patient´s rights and 23% 
were questions on health information. The 1,640 requests on patient rights were 
divided as follows: social rights (82%), problems related to access to treatments 
(10%), exams (3%) or physicians (3%). CONCLUSIONS: Our analysis showed that 
the demand for clarification regarding social rights and access to treatment reflect 
an unmet need for cancer patients and campaigns expanding the awareness of the 
population are warranted.
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OBJECTIVES: To determine how impactful patient-reported outcome (PRO) data 
from clinical trial programs are on market access decision making in oncology 
and other disease areas in decentralized markets. METHODS: A review of regula-
tory, health technology assessment (HTA), and third-party websites and published 
literature was the basis for six qualitative one-on-one interviews conducted with 
payer decision-makers (payers) in Brazil (1), Italy (1), Spain (1), and the United States 
(3) in 2014. RESULTS: Reviews conducted of HTA content and reimbursement deci-
sions indicate that HTA bodies have varying levels of familiarity and confidence 
in PRO data. All six payers indicated that it is worthwhile to collect PRO data in 
clinical trials for oncology, particularly in phase 3 and postmarketing studies. The 
payer in Spain was aware of a specific example where PRO data were crucial to 
decision-making for oncology. However, all six payers indicated that PRO data will 
increase in importance over the next 5 to 10 years and could be a key differentiator 
for new therapies. Payers did not differentiate the importance of PRO data by cancer 
type. All six payers indicated that the quality of the PRO evidence is paramount to 
consideration. In addition, they felt that PRO data currently have the most impact 
at the local level; one US payer noted there is significant opportunity to use PRO 
data to justify preferential product use and could be incorporated into hospital 
contracting. CONCLUSIONS: There are minimal requirements or guidelines specifi-
cally addressing whether and how health care decision-makers use PRO evidence; 
therefore, inclusion of PRO data in payer decision-making is currently determined 
on a case-by-case basis. There is growing recognition that the patient’s perspective 
is important in market access in decentralized markets.
PCN134
the dIsCoNNeCt BetweeN fuNdINg deCIsIoNs of CaNCeR dRugs aNd 
ComPaNIoN dIagNostIC tests IN CaNada
Poinas A., Wyatt G.
Wyatt Health Management, Oakville, ON, Canada
OBJECTIVES: More and more pharmaceuticals receive indications that require the 
use of companion diagnostic tests to identify subgroups of patients who would 
benefit from the therapy. Many mutations have been identified in cancer and the 
choice of treatment frequently depends on the result of a specific companion diag-
nostic test. In Canada, the pan Canadian Oncology Drug Review (pCODR) assesses 
cancer drugs based on clinical evidence, cost-effectiveness and patient input, to 
make recommendations to Canada’s provinces in guiding their funding decisions. 
The objective of this study is to determine how pCODR assesses drugs that require 
a companion diagnostic. METHODS: All pCODR recommendations as of were 
reviewed and those involving the use of a companion diagnostic were identified. 
Analysis of these recommendations was conducted to determine how companion 
diagnostic tests accompanying cancer drugs were reviewed by pCODR. RESULTS: 
pCODR has received 52 submissions since its inception and 39 recommendations 
have been issued. Of these recommendations, 9 involved the use of a companion 
diagnostic test. Both positive and negative comments around companion diagnos-
tic tests were found among the pCODR recommendations. (Results will be tabu-
lated) CONCLUSIONS: pCODR recommendations are dedicated to cancer drugs. 
However for those drugs requiring a companion diagnostic, pCODR also looks at 
the information related to these tests, e.g. costs and utility. However, there is no 
submission process for companion diagnostic tests at pCODR. Consequently, there 
is opportunity for inconsistency among the pCODR recommendations for cancer 
drugs and associated companion diagnostic tests.
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OBJECTIVES: Biomarker-driven prescribing is potentially highly cost-effective as it 
directs premium-priced treatment towards most-likely responders. As competition 
intensifies and collective treatment costs rise, however, this study examined the 
US and EU5 reimbursement and prescribing landscape for personalized medicines, 
focusing on non-small-cell lung cancer (NSCLC). METHODS: 100 US and 250 EU5 
medical oncologists were surveyed regarding their prescribing of biomarker-driven 
treatments for NSCLC. In addition, 30 US managed care organization (MCO) phar-
macy directors (PDs) were surveyed, and 15 reimbursement-influencing EU5 payers 
interviewed. RESULTS: Among surveyed US payers, 27% most associate biomarker-
driven prescribing with premium drug pricing, versus 13% and 17% who cited high 
likelihood of efficacy, and focused prescribing in most-appropriate patients, respec-
tively. Furthermore, crizotinib and afatinib are excluded/NDC blocked by the larg-
est commercial plans of > 25% of respondents, while plans of even more list these 
agents as non-preferred and likely to stay non-preferred, overwhelmingly due to 
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OBJECTIVES: Our aim was to develop a conceptual framework in patients with 
locally recurrent or metastatic triple-negative breast cancer (TNBC) through a litera-
ture review and patient interviews. METHODS: A literature review on health-related 
quality of life (HRQoL) in advanced breast cancer was performed using the EMBASE 
database. Clinical experts were asked to identify key HRQoL concepts related to 
TNBC. Two trained psychologists conducted semi-structured individual interviews 
with patients with TNBC in the UK and France until saturation of concepts was 
reached. Patients were asked to cite important concepts related to the impact of 
disease on HRQoL and to rate them. Following ISPOR guidelines, qualitative analysis 
was performed by coding all patient responses. Code frequency and bother ratings 
were used to identify salient disease and treatment impact. RESULTS: Two clini-
cal experts and 28 patients were interviewed (age range, 26-83 years). Twenty-one 
patients (75%) had metastatic disease and 7 (25%) had locally recurrent cancer. 
Results of the patient interviews indicate that TNBC affects multiple dimensions 
of HRQoL: psychological functioning (shame/embarrassment, anger, worry, depres-
sion), role functioning (work limitation, social/leisure activities), energy levels, daily 
living and physical dimensions. Patients experienced distress because of fear of 
death, fear of disease progression, a changed body image, and concern about their 
loved ones. Patients associated a greater decrease in HRQoL with chemotherapy 
compared to radiotherapy and surgery as it resulted in a large range of impairments 
that impacted all relevant life domains: psychological and physical health, partici-
pation in social and occupational activities, and functioning in daily living. Coping 
strategies described by patients included living life day-by-day and prioritizing life 
differently. CONCLUSIONS: TNBC and its treatment have a profound effect on all 
aspects of patients’ lives. Results of this study were used to inform the inclusion of 
patient-reported outcome measures in phase 3 clinical development.
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OBJECTIVES: To validate the short version of the QLQ-C30 obtained for patients 
with non-small-cell lung cancer in patients with head and neck, prostate, breast or 
cervix cancer METHODS: We analyzed data of 636 patients distributed: 237 diag-
nosed with head and neck cancer, 146 diagnosed with breast cancer, 140 diagnosed 
with cervix cancer and 113 diagnosed with prostate cancer. The analysis followed 
a 4-step approach. First, we conducted a Mokken nonparametric item response 
analysis to ascertain the QLQ-C30 dimensionality and separate several scale if 
appropriate. Second, we conducted a parametric Samejima’s graded response model 
(GRM) to assess the item characteristics and information for each scale. Third, we 
did a confirmatory factor analysis (CFA) to test the scales unidimensionality and 
to obtain standardized factor loadings to suggest a reduced version of the QLQ. 
Finally, we assessed the discriminative validity of the reduced version by using 
receiver-operator curve (ROC) analysis. RESULTS: In this study the reduction of 
the general questionnaire QLQ-C30 cancer 30 items to 6 scores are obtained. First it 
was found that 6 scores account for a 63.38% of the overall variability. Furthermore 
it was found that 6 score explained 62.3% of the variability in patients with head 
and neck cancer Nimotuzumab tratadados with a 65.53% for patients with pros-
tate cancer treated with Nimotuzumab or CIMAvaxEGF, a 61.80% for patients with 
breast cancer treated with NGcGM3 and 63.83% for patients with cervical cancer 
treated with Nimotuzumab. 6 scores obtained correspond to the score of physical, 
emotional and social functional scale and the scale of symptoms of nausea and 
vomiting. CONCLUSIONS: The EORTC reduced scale was invariant for each indica-
tions of cancer studied; it presents good psychometric properties and includes a 
unidimensional structure of patient-perceived quality of life.
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OBJECTIVES: Patients’ groups and advocacy play an important role in the oncol-
ogy field. Understanding oncologic patients’ needs may improve prevention, early 
detection, quality-of-life and legal rights, reducing the burden of the disease. Few 
studies, however, have focused on the needs of this specific population in Brazil. The 
present analysis can contribute to develop an awareness campaign besides advocate 
to cancer patient needs. Our objective was to identify and describe the main needs 
of cancer patients in Brazil. METHODS: We analyzed the PAP program database 
from 01/2013 to 08/2014. This is a support and personalized counseling program 
dedicated to cancer patients and maintained by Oncoguia Institute, an independent 
nonprofit institution. We retrieved and described the applicants’ profiles (patient, 
family, specialty society, physicians, etc) and type of required information (patient 
rights, related to health/quality of life or access to diagnostic or treatment proce-
dures). RESULTS: In the aforementioned period, 2,214 applicants received 2,586 
